Sickle Cell Disease

Introduction and Genetics

• Sickle cell disease (SCD) represents a group of hemoglobinopathies characterized by the inheritance of the sickle hemoglobin (HbS) gene.
• Sickle cell anemia (homozygous HbSS) occurs when both $\beta$-globin alleles carry the sickle cell pathogenic variant (${\beta }^s$).
• The term "sickle cell disease" encompasses homozygous HbSS as well as compound heterozygous states, such as HbSC disease, HbS${\beta }^0$-thalassemia, and HbS${\beta }^{+}$-thalassemia.
• The disorder exhibits an autosomal codominant inheritance pattern.
• The underlying genetic defect is a single base-pair change (thymine for adenine) at the 6th codon of the β-globin gene on chromosome 11, resulting in the substitution of the amino acid valine for glutamic acid.
• In India, sickle cell anemia has a total gene frequency of 4.3%, with a particularly high incidence among the tribal populations of Orissa, Maharashtra, Madhya Pradesh, Jharkhand, and Gujarat.
• The sickle cell trait (HbAS), which is a heterozygous state, provides a selective evolutionary advantage by conferring resistance against Plasmodium falciparum malaria (balanced polymorphism).

Pathophysiology

• Normal hemoglobin molecules do not interact with one another; however, deoxygenated HbS molecules interact to form rigid polymers.
• This polymerization causes conformational cellular alterations, distorting red blood cells (RBCs) into a rigid, sickled shape.
• Sickled RBCs are poorly deformable and prematurely destroyed, leading to a markedly shortened RBC life span (10–20 days) and chronic hemolytic anemia.
• Intravascular sickling primarily occurs in postcapillary venules and leads to mechanical obstruction by sickled erythrocytes, activated leukocytes, and platelets.
• Vaso-occlusion results in tissue ischemia and subsequent ischemia-reperfusion injury, which is the central event driving acute complications.
• The pathophysiology is further driven by hemolysis-associated reduction in nitric oxide bioavailability, chronic inflammation, oxidative stress, altered hemostasis, impaired fibrinolysis, increased blood viscosity, and endothelial dysfunction.
• Fetal hemoglobin (HbF, $\gamma$-globin) exerts a protective effect by decreasing the polymer content within the cells; sustained elevations in HbF ( >20%) strongly correlate with a reduction in clinical severity.

Diagnostic Evaluation

Newborn Screening and Early Diagnosis

• Mandatory newborn screening programs utilize thin-layer isoelectric focusing (IEF) or high-performance liquid chromatography (HPLC) to detect abnormal hemoglobins from dried blood spots.
• Hemoglobins are reported in order of quantity. An "FS" pattern indicates HbSS, HbS${\beta }^0$-thalassemia, or HbS-Hereditary Persistence of Fetal Hemoglobin (HPFH).
• An "FSC" pattern denotes HbSC disease, while an "FSA" pattern suggests HbS${\beta }^{+}$-thalassemia.
• A confirmatory hemoglobin identification analysis and complete blood count (CBC) must be performed at 6 to 12 months of age, alongside parental testing to establish the definitive genotype.
• Prenatal diagnosis can be performed accurately using DNA analysis from a chorionic villus biopsy (10–14 weeks) or amniocentesis (15–20 weeks).

Laboratory Findings in Older Children

• Complete Blood Count: Reveals moderate to severe anemia (baseline hemoglobin typically 6–11 g/dL in HbSS), reticulocytosis (5–30%), and commonly neutrophilia and thrombocytosis.
• Red Cell Indices: Mean corpuscular volume (MCV) is generally normal in HbSS but microcytic if there is concurrent $\alpha$-thalassemia trait, HbSC, or HbS$\beta$-thalassemia.
• Peripheral Blood Smear: Demonstrates sickled cells, target cells, increased polychromasia, nucleated RBCs, and Howell-Jolly bodies (indicating functional asplenia).
• Hemoglobin Electrophoresis: HbS migrates slower than HbA; in homozygous HbSS, HbS constitutes 80–96% of the hemoglobin, alongside 2–20% HbF, and no HbA.

Acute Clinical Complications

Vaso-Occlusive Pain Event (VOE)

• Acute sickle cell pain is the cardinal clinical feature and the most common reason for medical evaluation; it is characterized by unremitting discomfort resulting from episodic microvascular occlusion and tissue ischemia.
• Dactylitis (hand-foot syndrome) is frequently the first manifestation of VOE, occurring as symmetric or unilateral swelling of the hands and feet in 50% of infants by their second year of life.
• Pain episodes can be precipitated by physical stress, infection, dehydration, hypoxia, acidosis, or cold exposure, though many occur without identifiable triggers.
• Treatment requires rapid, stepwise escalation of analgesia, starting with NSAIDs or acetaminophen, progressing rapidly to short-acting and long-acting systemic opioids (e.g., intravenous morphine).

Acute Chest Syndrome (ACS)

• ACS is the leading cause of mortality and the second most common cause of hospitalization in children with SCD.
• It is defined by a new radiodensity on a chest radiograph accompanied by fever, respiratory distress, hypoxia, cough, or chest pain.
• Etiologies include pulmonary infection (commonly Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydia spp.), fat emboli from infarcted bone marrow, or hypoventilation secondary to severe rib/chest pain.
• Management includes continuous pulse oximetry, judicious intravenous fluids (avoiding overhydration), broad-spectrum antibiotics (a macrolide plus a cephalosporin), incentive spirometry, bronchodilators, and simple or exchange RBC transfusions for hypoxia or progressive clinical decline.

Acute Splenic Sequestration

• Characterized by the rapid pooling of massive amounts of blood in the spleen, resulting in sudden splenomegaly, left-sided abdominal pain, a precipitous drop in hemoglobin ($<3$ g/dL), and potential hypovolemic shock.
• It is most prevalent in infants and young children with HbSS (between 6 months and 2 years of age) but can occur into adulthood in patients with HbSC or HbS${\beta }^{+}$-thalassemia.
• Treatment consists of rapid volume resuscitation and careful RBC transfusion to reverse hypovolemia and mobilize sequestered cells. Transfusion must be conservative (e.g., 5 mL/kg) to prevent rebound hyperviscosity once sequestered RBCs re-enter the circulation.

Aplastic Crisis

• Primarily caused by human parvovirus B19 infection, which directly infects erythroid progenitors, resulting in a temporary arrest of RBC production.
• Clinically presents with fever, profound anemia, and striking reticulocytopenia.
• It is highly contagious; patients require isolation. Management is supportive, relying on RBC transfusions until spontaneous marrow recovery occurs, typically heralded by nucleated RBCs and a rising reticulocyte count.

Cerebrovascular Accidents (Stroke)

• Without screening, overt strokes affect approximately 11% of patients with HbSS before age 20, peaking in the first decade of life.
• Strokes are predominantly ischemic in children, resulting from chronic intimal injury, fibroblast proliferation, and progressive stenosis or occlusion of the distal internal carotid and middle cerebral arteries.
• Any acute focal neurological deficit warrants immediate evaluation, neuroimaging (MRI/MRA if available, or CT to rule out hemorrhage), and prompt exchange transfusion to lower the HbS fraction to <30%.

Infections and Bacteremia

• Splenic dysfunction begins as early as 6 months, progressing to complete functional autosplenectomy (fibrosis) by 5 years of age.
• This confers a 300- to 600-fold increased risk of overwhelming, life-threatening sepsis and meningitis, particularly from encapsulated organisms like S. pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis, as well as Salmonella species.
• Fever ($>{40.0}^{\circ }$C or ${104}^{\circ }$F) is a medical emergency requiring immediate evaluation, blood cultures, and empiric broad-spectrum intravenous antibiotics (e.g., ceftriaxone).

Chronic Complications and End-Organ Damage

Neurological and Cognitive

• Silent cerebral infarcts (diagnosed via MRI as T2-weighted hyperintensities without overt focal deficits) occur in about 35-39% of children with HbSS.
• These lesions are associated with neurocognitive deficits, poor academic performance, and an increased risk for future overt strokes.

Pulmonary and Cardiovascular

• Pulmonary hypertension is a major risk factor for premature mortality, evaluated initially by echocardiography (tricuspid regurgitant velocity) and confirmed by right-sided heart catheterization.
• Asthma is highly prevalent and directly exacerbates ACS, VOE, and stroke risk.
• Cardiovascular findings universally include a hyperdynamic state, cardiomegaly, left ventricular hypertrophy, flow murmurs, and frequently a prolonged QTc interval.

Renal and Genitourinary

• Sickle nephropathy begins with hyposthenuria (an inability to concentrate urine), resulting in obligatory polyuria and susceptibility to dehydration.
• Progressive injury manifests as hematuria, papillary necrosis, microalbuminuria, overt proteinuria, and potentially nephrotic syndrome and chronic renal failure.
• Nocturnal enuresis affects up to 33% of children and can persist into late adolescence (9%).
• Priapism (prolonged or stuttering painful erections) affects 30–45% of males, often beginning in childhood; failure of detumescence can lead to permanent erectile dysfunction.

Skeletal and Cutaneous

• Avascular necrosis (AVN) of the femoral and humeral heads is common (cumulative incidence of 22%) due to repetitive ischemia-reperfusion injury of the articular surfaces.
• Bone marrow expansion results in cortical thinning, classical "hair-on-end" skull radiograph appearance, and "fish-mouth" vertebral deformities.
• Chronic, recalcitrant leg ulcers commonly develop over the medial or lateral malleoli in older children and adolescents due to increased venous pressure and local ischemia.

Hepatobiliary and Ocular

• Chronic hemolysis leads to elevated indirect bilirubin, resulting in pigment gallstones (cholelithiasis) in the majority of patients.
• Sickle retinopathy (both nonproliferative and proliferative "sea fan" neovascularization) can cause vitreous hemorrhage and retinal detachment; it is especially prevalent in HbSC disease.

Management and Preventive Care

Infection Prophylaxis

• Oral penicillin V prophylaxis must be initiated by 2 to 3 months of age (125 mg BID for $<3$ years; 250 mg BID for $\ge 3$ years) and continued at least until age 5 to prevent pneumococcal sepsis.
• Routine childhood immunizations must be supplemented with the 23-valent pneumococcal polysaccharide vaccine (at age 2, with a booster 5 years later), meningococcal vaccines, and annual influenza vaccines.

Transcranial Doppler (TCD) Screening

• TCD is utilized for primary stroke prevention by measuring the time-averaged mean maximum (TAMM) blood flow velocity in the cerebral arteries.
• Annual screening is mandated for children with HbSS or HbS${\beta }^0$-thalassemia between 2 and 16 years of age.
• A TAMM velocity $\ge 200$ cm/sec is abnormal and indicates a high risk of stroke, necessitating the immediate initiation of chronic RBC transfusion therapy to maintain HbS <30%.

Red Blood Cell Transfusion Therapy

• Indications: Acute indications include stroke, ACS, splenic sequestration, aplastic crisis, and preoperative preparation for general anesthesia (targeting a preoperative Hb of 10 g/dL). Chronic indications include primary/secondary stroke prevention and recurrent severe ACS.
• Methods: Automated erythrocytapheresis is preferred for chronic management to minimize net iron balance, but manual exchange or simple transfusions are also utilized.
• Complications: Patients require extended phenotypic matching (at minimum for C, E, and K antigens) due to a high risk of alloimmunization (17.6%).
• Iron Overload: Chronic transfusions inevitably lead to iron overload, necessitating rigorous monitoring (serum ferritin, hepatic MRI) and the use of iron chelating agents such as oral deferasirox, oral deferiprone, or subcutaneous deferoxamine.

Disease-Modifying and Curative Therapies

Pharmacological Agents

• Hydroxyurea: The standard of care disease-modifying agent. It increases HbF production, improves RBC hydration, decreases RBC adhesion, and lowers leukocyte and reticulocyte counts. It significantly reduces the frequency of VOE, ACS, dactylitis, and the need for transfusions. It is recommended for all children with HbSS or HbS${\beta }^0$-thalassemia beginning at 9 months of age, starting at 20 mg/kg/day and escalating to a maximum tolerated dose of 35 mg/kg/day. Stringent monitoring for myelosuppression is required.
• L-Glutamine: Approved for children $\ge 5$ years of age. It alters the redox state of RBCs and decreases endothelial adhesion, significantly reducing the frequency of pain episodes and hospitalizations.
• Voxelotor: A small molecule inhibitor of HbS polymerization approved for children $\ge 4$ years of age. It shifts the hemoglobin oxygen dissociation curve and directly reduces hemolysis, increasing baseline hemoglobin levels.
• Crizanlizumab: A humanized anti-P-selectin monoclonal antibody administered monthly via IV, approved for patients $\ge 16$ years of age. It inhibits cellular adhesion, reducing the annual rate of VOE by roughly 50%.

Hematopoietic Stem Cell Transplantation (HSCT)

• HSCT remains the only established curative therapy for SCD.
• Outcomes are excellent (>90% survival and >85% disease-free survival) when utilizing an HLA-identical matched sibling donor, particularly if performed early in childhood before the onset of severe organ damage or allosensitization.
• Indications for HSCT include overt stroke, recurrent ACS, recurrent debilitating VOE, sickle nephropathy, and multiple joint AVN.

Gene Therapy

• The FDA approved two ex vivo gene therapies in 2023 for patients $\ge 12$ years of age with recurrent vaso-occlusive crises following myeloablative conditioning.
• Casgevy (exagamglogene autotemcel): Utilizes CRISPR/Cas9 gene editing to inactivate the BCL11A gene in autologous hematopoietic stem cells. BCL11A normally suppresses $\gamma$-globin expression; its inactivation massively upregulates HbF production, inhibiting HbS polymerization.
• Lyfgenia (lovotibeglogene autotemcel): Uses a lentiviral vector for gene addition, inserting a modified anti-sickling $\beta$-globin gene (${\beta }^{A-T87Q}$) to increase functional adult-like hemoglobin levels.